# BridgeBio Data Shows Acoramidis Reduces Heart Hospitalizations Compared to Tafamidis

- URL: https://stocks.freetheai.org/news/bridgebio-data-shows-acoramidis-reduces-heart-hospitalizations-compared-to-c97e4b
- Published: 2026-10-11T18:30:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:BBIO](https://stocks.freetheai.org/symbols/NASDAQ-BBIO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented real-world health record data demonstrating that its drug acoramidis reduced adverse clinical outcomes in heart disease patients compared to tafamidis. In an independent observational analysis of nearly 2,700 patients with transthyretin amyloid cardiomyopathy, acoramidis was linked to an 18% lower risk of a composite endpoint that included mortality, hospitalizations, new-onset atrial fibrillation, and diuretic escalation.

The study highlights a significant reduction in hospital admissions for patients taking acoramidis. Compared to those on tafamidis, patients taking acoramidis experienced a 27% lower risk of cardiovascular hospitalizations, a 27% lower risk of heart failure hospitalizations, and a 25% lower risk of overall hospitalizations. Additional clinical trial sub-analyses indicated that preventing hospitalizations is crucial, as mortality risk doubles after a single cardiovascular hospitalization and quadruples after two or more.

Researchers noted that while observational health record studies have inherent limitations and relatively short follow-up periods, these real-world findings mirror previous claims-based studies favoring acoramidis. The full observational study is currently undergoing peer review for publication in a scientific journal, and ongoing mature data collections will offer further insights into long-term outcomes like mortality rates.

## Key points

- Acoramidis showed an 18% lower risk of composite adverse events compared to tafamidis in a real-world study of 2,684 heart disease patients.
- Patients on acoramidis experienced a 27% reduction in heart failure hospitalizations and a 25% reduction in overall hospitalizations compared to tafamidis.
- Acoramidis also reduced diuretic intensification, an early indicator of worsening heart disease, by 17%.
- Phase 3 sub-analyses demonstrated that mortality risk quadruples after two or more cardiovascular hospitalizations.

## Questions and answers

### What did the real-world study find about acoramidis versus tafamidis?

The study showed acoramidis was associated with an 18% lower risk of a composite endpoint of death, hospitalizations, atrial fibrillation, and diuretic escalation compared to tafamidis.

### How does acoramidis impact hospitalization rates for ATTR-CM patients?

Acoramidis was associated with a 27% lower risk of cardiovascular and heart failure hospitalizations, as well as a 25% lower risk of all-cause hospitalizations compared to tafamidis.

### Why is reducing hospitalizations important for ATTR-CM treatment?

Trial analyses show that mortality risk approximately doubles after a single cardiovascular hospitalization and quadruples after two or more, making hospitalization prevention a primary treatment goal.